urea and su 11248

urea has been researched along with su 11248 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM	1
Achour, H; Bauer, S; Blay, JY; Choucair, K; Gelderblom, H; George, S; Heinrich, MC; Mehren, MV; Nemunaitis, J; Ruiz-Soto, R; Schöffski, P; Zalcberg, J	1
Cai, S; Cao, H; Deng, Y; Dong, J; Huang, Z; Li, J; Shen, L; Wu, X; Zhang, J; Zhou, Y	1

Trials

2 trial(s) available for urea and su 11248

Article	Year
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future oncology (London, England), 2020, Volume: 16, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Naphthyridines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Research Design; Sunitinib; Survival Rate; Urea; Young Adult	2020
Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 08-15, Volume: 28, Issue:16 Topics: China; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Naphthyridines; Sunitinib; Urea	2022

Article

Year

Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.

Future oncology (London, England), 2020, Volume: 16, Issue:1

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Naphthyridines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Research Design; Sunitinib; Survival Rate; Urea; Young Adult

2020

Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 08-15, Volume: 28, Issue:16

Topics: China; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Naphthyridines; Sunitinib; Urea

2022

Other Studies

1 other study(ies) available for urea and su 11248

Article	Year
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11 Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea	2008

Article

Year

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea

2008